Ironwood Competitors
| IRWD Stock | USD 4.42 0.17 3.70% |
Ironwood Pharmaceuticals vs Cellectis Correlation
Good diversification
The correlation between Ironwood Pharmaceuticals and CLLS is -0.04 (i.e., Good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Ironwood Pharmaceuticals and CLLS in the same portfolio, assuming nothing else is changed.
Moving together with Ironwood Stock
Moving against Ironwood Stock
| 0.86 | GNLX | Genelux Common | PairCorr |
| 0.86 | LYRA | Lyra Therapeutics | PairCorr |
| 0.77 | ABP | Abpro Holdings Buyout Trend | PairCorr |
| 0.73 | DWTX | Dogwood Therapeutics | PairCorr |
| 0.7 | EDIT | Editas Medicine | PairCorr |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Ironwood Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Ironwood Pharmaceuticals Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Ironwood Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Ironwood and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Ironwood Pharmaceuticals does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Ironwood Stock performing well and Ironwood Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Ironwood Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| CGC | 4.58 | 0.18 | 0.02 | 0.57 | 4.70 | 8.55 | 66.41 | |||
| TKNO | 2.91 | (1.28) | 0.00 | (2.01) | 0.00 | 4.75 | 23.61 | |||
| LFCR | 2.19 | 0.06 | 0.03 | 0.13 | 2.32 | 6.17 | 16.31 | |||
| ACB | 2.69 | (0.32) | 0.00 | (0.45) | 0.00 | 4.36 | 30.41 | |||
| BIOA | 4.45 | 1.64 | 0.48 | 3.52 | 2.60 | 13.88 | 33.50 | |||
| GNLX | 4.08 | (1.67) | 0.00 | (0.90) | 0.00 | 5.67 | 32.40 | |||
| NPCE | 2.37 | 0.14 | 0.09 | 0.16 | 2.14 | 5.40 | 17.92 | |||
| ALDX | 3.69 | 0.28 | 0.05 | 0.75 | 4.23 | 8.64 | 42.93 | |||
| SLN | 3.05 | (0.47) | 0.00 | (0.78) | 0.00 | 6.88 | 23.80 | |||
| CLLS | 3.84 | 0.34 | 0.06 | 0.65 | 4.49 | 9.24 | 29.31 |
Cross Equities Net Income Analysis
Compare Ironwood Pharmaceuticals and related stocks such as Canopy Growth Corp, Alpha Teknova, and Lifecore Biomedical Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CGC | (26.9 K) | (21.4 K) | (64.6 K) | (932.9 K) | (8.9 M) | (3.5 M) | (16.6 M) | (54.1 M) | (670.1 M) | (1.3 B) | (1.7 B) | (310 M) | (3.3 B) | (657.3 M) | (598.1 M) | (8.9 M) | (9.4 M) |
| TKNO | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | 3.6 M | (9.8 M) | (47.5 M) | (36.8 M) | (26.7 M) | (24.1 M) | (25.3 M) |
| LFCR | (4.2 M) | 12.7 M | 22.6 M | 19.1 M | 13.5 M | (11.6 M) | 10.6 M | 24.8 M | 2.1 M | (38.2 M) | (32.3 M) | (97.4 M) | (116.7 M) | 12 M | (38.7 M) | (34.8 M) | (33.1 M) |
| ACB | 1.3 K | (315.8 K) | (393.5 K) | (399.7 K) | (9.5 M) | (5.7 M) | (13 M) | 71.9 M | (293.5 M) | (3.3 B) | (693.6 M) | (1.7 B) | (816.6 M) | (69.3 M) | 1.6 M | 1.4 M | 1.5 M |
| BIOA | (33.2 M) | (33.2 M) | (33.2 M) | (33.2 M) | (46.4 M) | (37.2 M) | (22.5 M) | (98.2 M) | (39.7 M) | (39.7 M) | (39.7 M) | (39.7 M) | (39.7 M) | (63.9 M) | (71.1 M) | (64 M) | (67.2 M) |
| GNLX | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (14.9 M) | (17.8 M) | (5.2 M) | (28.3 M) | (29.9 M) | (26.9 M) | (28.2 M) |
| NPCE | (30 M) | (30 M) | (30 M) | (30 M) | (30 M) | (30 M) | (30 M) | (30 M) | (30 M) | (30 M) | (24.3 M) | (36.1 M) | (47.1 M) | (33 M) | (27.1 M) | (24.4 M) | (25.6 M) |
| ALDX | (2.4 M) | (2.4 M) | (23.1 M) | 13.1 M | (5.2 M) | (12.1 M) | (18.7 M) | (22.3 M) | (38.9 M) | (60.8 M) | (37.6 M) | (57.8 M) | (62 M) | (37.5 M) | (55.9 M) | (50.3 M) | (47.8 M) |
| SLN | (874 K) | (5.7 M) | (26.3 M) | (9 M) | (11.1 M) | (6.6 M) | (8.4 M) | (1.6 M) | (18.4 M) | (19.6 M) | (32.5 M) | (39.4 M) | (50.3 M) | (43.3 M) | (45.3 M) | (40.8 M) | (38.7 M) |
| CLLS | (4.4 M) | (30.9 M) | (29.5 M) | (84.3 M) | 24.3 K | (22.5 M) | (63.9 M) | (99.4 M) | (78.7 M) | (90.7 M) | (72.6 M) | (86.3 M) | (98.7 M) | (101.1 M) | (36.8 M) | (33.1 M) | (34.7 M) |
Ironwood Pharmaceuticals and related stocks such as Canopy Growth Corp, Alpha Teknova, and Lifecore Biomedical Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Ironwood Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Ironwood Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Ironwood Pharmaceuticals Competitive Analysis
The better you understand Ironwood Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Ironwood Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Ironwood Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Ironwood Pharmaceuticals Competition Performance Charts
Five steps to successful analysis of Ironwood Pharmaceuticals Competition
Ironwood Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Ironwood Pharmaceuticals in relation to its competition. Ironwood Pharmaceuticals' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Ironwood Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Ironwood Pharmaceuticals' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Ironwood Pharmaceuticals, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Ironwood Pharmaceuticals position
In addition to having Ironwood Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Target Outcome ETFs Thematic Idea Now
Target Outcome ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Target Outcome ETFs theme has 86 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Target Outcome ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Ironwood Pharmaceuticals Correlation with its peers. For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Will Biotechnology sector continue expanding? Could Ironwood diversify its offerings? Factors like these will boost the valuation of Ironwood Pharmaceuticals. Market participants price Ironwood higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Ironwood Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 10.468 | Earnings Share 0.18 | Revenue Per Share | Quarterly Revenue Growth 0.333 | Return On Assets |
Investors evaluate Ironwood Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Ironwood Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Ironwood Pharmaceuticals' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Ironwood Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ironwood Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Ironwood Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.